Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial -

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Obstetrics and gynaecology
Summary
Study (n=265) found median PFS longer in olaparib vs. placebo group (11•2 vs. 4•3 months; HR 0•18 [0•10—0•31]; p<0•0001) in patients with BRCA mutation. At 2nd interim analysis, OS did not differ between groups. Similar findings found in mutated and wild-type BRCA groups.
UKMi comment
Olaparib is a poly(ADP-ribose) polymerase inhibitor currently in phase III trials in BRCA mutated ovarian cancer patients who are in complete or partial response following platinum-based chemotherapy in the first-line setting (SOLO 1), and in the relapsed setting (SOLO 2). EU and US filings are planned for 2017 (first-line setting) and 2016 (relapsed setting).
Related links: Comment